## RVTY: Revvity, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.63 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($93.49)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Allspring Global Investments Holdings LLC Has $70.79 Million Stock Holdings in Revvity Inc. $RVTY**
- Source: MarketBeat | 20260101T081006 | Somewhat-Bullish | Relevance: 100%
- Allspring Global Investments Holdings LLC significantly increased its stake in Revvity Inc. (NYSE:RVTY) by 14,741.7% in Q3, now holding 771,470 shares valued at $70.79 million. This makes up about 0.66% of the company's stock. Revvity recently reported earnings of $1.18 EPS, beating estimates, and announced a $1.00 billion stock buyback program and a quarterly dividend.

**2. Revvity Inc. (NYSE:RVTY) Given Average Recommendation of "Hold" by Brokerages**
- Source: MarketBeat | 20251231T200843 | Neutral | Relevance: 100%
- Revvity Inc. (NYSE:RVTY) has received an average "Hold" recommendation from fourteen brokerages, with an average twelve-month price target of $115.25. The company announced a $1.00 billion stock buyback plan and a quarterly dividend of $0.07 per share. Institutional investors have significantly increased their holdings, with 86.65% of the stock owned by hedge funds and other institutional investors.

**3. Hereâ€™s Why Diamond Hill Mid Cap Composite Purchased Revvity (RVTY) in Q3**
- Source: Insider Monkey | 20251231T124735 | Somewhat-Bullish | Relevance: 100%
- Diamond Hill Mid Cap Strategy acquired shares of Revvity, Inc. (NYSE: RVTY) in Q3 2025 finding its price undervalued compared to its long-term growth outlook. Revvity, a life sciences tools and diagnostics company, has upgraded its product portfolio to higher-margin offerings. Despite market rallies, Diamond Hill capitalized on investor concerns about biopharmaceutical policy uncertainty to add Revvity at a discount to its intrinsic value estimate.

**4. What Makes The Cooper Companies (COO) an Investment Bet?**
- Source: Insider Monkey | 20251231T124259 | Somewhat-Bullish | Relevance: 64%
- Diamond Hill Capital's Mid Cap Strategy initiated a position in The Cooper Companies (NASDAQ: COO) during Q3 2025, viewing it as an attractive investment despite current transitory headwinds. The company, a leader in contact lenses and women's health, is expected to benefit from long-term growth in its markets. While Cooper Companies isn't among the top 30 hedge fund picks, 56 hedge funds held positions at the end of Q3, indicating significant institutional interest.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $115 | $105 | +10% |
| 2025-12-15 | Wells Fargo | $107 | $102 | +5% |
| 2025-12-09 | Goldman Sachs | $105 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-09 | Goldman Sachs | init | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- T. Rowe Price Invest: 19.9% (-0.6%)
- Vanguard Group Inc: 11.9% (-4.0%)
- Blackrock Inc.: 8.2% (+4.4%)
- Edgepoint Investment: 7.6% (+26.3%)
- Price (T.Rowe) Assoc: 7.2% (+2.4%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +4.0% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.63 indicates undervaluation relative to growth. Forward P/E 18.5x stretched relative to 8% growth. Analyst sentiment positive (2 raises, avg +7%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.4B |
| Beta | 1.06 |
| 52W Range | $81.36 - $128.29 |
| Short Interest | 7.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.63 |
| Forward P/E | 18.5 |
| Current P/E | 20.0 |
| YoY Growth | 7.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -4.0% to 0.1% (+4.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.9pp (needs >4.0% for momentum thesis). MRS_5 at 1.6% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.04x) but short-term weakness (below SMA20). RSI neutral at 51. OFD pattern: +MLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.08% (CS: 40) | Neutral |
| RSI_14 | 51.0 | Neutral |
| MACD Histogram | -0.29 | Bearish |
| vs SMA20 | 0.995x | Below |
| vs SMA50 | 1.011x | Above |
| vs SMA200 | 1.041x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $98.15
- **Stop Loss:** $93.49 (4.7% risk)
- **Target:** $107.47 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 309
- **Position Value:** $30,328.35
- **Portfolio %:** 30.33%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-01-26 (Est: $1.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.14 | $1.18 | +3.6% |
| 2025Q2 | $1.14 | $1.18 | +3.4% |
| 2025Q1 | $0.95 | $1.01 | +6.4% |
| 2024Q4 | $1.38 | $1.42 | +3.1% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*